In vivo efficiency of targeted norfloxacin against persistent, isoniazid-insensitive, Mycobacterium bovis BCG present in the physiologically hypoxic mouse liver

Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering

Many of the strategies currently being explored in the field of tissue engineering involve the combination of cells and degradable engineered scaffolds for the regeneration of biological tissues. However, infection of the wound or the scaffold itself results in failure of healing. Therefore, a new area of development in the field is the synthesis of polymer-based scaffolds that inherently have the ability to resist microbial infection as degradation occurs and new tissue replaces the scaffold. These scaffolds, defined as inherently antimicrobial biodegradable polymers (IABPs), can be classified based on their monomeric components as follows: (1) traditional antimicrobials (such as beta-lactams, fluoroquinolones, glycopeptides, and aminoglycosides), (2) naturally derived compounds (such as extracellular matrix components, chitosan, and antimicrobial peptides), and (3) novel synthetic antimicrobials. After validation of chemical synthesis as well as physicochemical characterization of a newly created IABP, thorough in vitro and in vivo assays must be conducted to ensure antimicrobial efficacy as well as biocompatibility as a tissue-engineered scaffold system. In this review, we will introduce existing IABPs, discuss the current platforms that have been developed for the synthesis of IABPs, and highlight future directions as well as challenges in the field.

RegA, the regulator of the two-component system RegB/RegA of Brucella suis, is a controller of both oxidative respiration and denitrification required for chronic infection in mice

Adaptation to oxygen deficiency is essential for virulence and persistence of Brucella inside the host. The flexibility of this bacterium with respect to oxygen depletion is remarkable, since Brucella suis can use an oxygen-dependent transcriptional regulator of the FnrN family, two high-oxygen-affinity terminal oxidases, and a complete denitrification pathway to resist various conditions of oxygen deficiency. Moreover, our previous results suggested that oxidative respiration and denitrification can be simultaneously used by B. suis under microaerobiosis. The requirement of a functional cytochrome bd ubiquinol oxidase for nitrite reductase expression evidenced the linkage of these two pathways, and the central role of the two-component system RegB/RegA in the coordinated control of both respiratory systems was demonstrated. We propose a scheme for global regulation of B. suis respiratory pathways by the transcriptional regulator RegA, which postulates a role for the cytochrome bd ubiquinol oxidase in redox signal transmission to the histidine sensor kinase RegB. More importantly, RegA was found to be essential for B. suis persistence in vivo within oxygen-limited target organs. It is conceivable that RegA acts as a controller of numerous systems involved in the establishment of the persistent state, characteristic of chronic infections by Brucella.

Bioresorbable polyelectrolyte amphiphiles as nanosized carriers for lipophilic drug solubilization and delivery

Starting from drug carriers and drug-delivery systems described in the literature, this article examines more specifically those that are relevant to the field of nanocarriers composed of a degradable hydrophilic polyelectrolyte backbone with pendent hydrophobes arranged to form comb-like co-polymers. Advantage is taken of the nanosized, lipophilic pocket-bearing multimolecule aggregates formed in aqueous media by such amphiphilic polyelectrolytes to accommodate water-insoluble drug molecules according to a phenomenon named macromolecular microencapsulation. Comments are also made on the criteria to be fulfilled by nanosized polymeric drug carriers. These carriers require a size or molar mass high enough to avoid renal excretion and thus be retained in the body for longer periods of time than the free drug. Since they nevertheless have to be eliminated from the body (bioresorption), they must be degraded at the end of use. In situ degradation is an important criterion that is taken into account by using special polyelectrolytes that belong to the class of the so-called "artificial biopolymers". Artificial biopolymers are made of pro-metabolite units than generate metabolite upon degradation, thus resulting in metabolisation of degradation end-products if intermediates are not excreted before. Aggregates of amphiphilic polyanions derived from malic acid, citric acid, L-lysine and L-serine are presented to support the concept of macromolecular microencapsulation. Comparison is made with non-polyelectrolytic systems with similar structures.

Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies

The use of laboratory animals is critical to the discovery and in vivo pre-clinical testing of new drugs and drug combinations for use in humans. M. tuberculosis infection of mice, rats, guinea pigs, rabbits and non-human primates are the most commonly used animal models of human tuberculosis. While granulomatous inflammation characterizes the most fundamental host response to M. tuberculosis aerosol infection in humans and animals, there are important species differences in pulmonary and extra-pulmonary lesion morphology which may influence responses to drug therapy. Lesions that progress to necrosis or cavitation are common, unfavorable host responses in naturally occurring tuberculosis of humans, but are not seen consistently in experimental infections in most animal model species. The importance of these unique lesion morphologies is that they represent irreversible tissue damage that can harbor persistent bacilli which are difficult to treat with standard therapies. Understanding the differences in host response to experimental tuberculosis infections may aid in selecting the most appropriate animal models to test drugs that have been rationally designed to have specific mechanisms of action in vivo. A better understanding of lesion pathogenesis across species may also aid in the identification of novel therapeutic targets or strategies that can be used alone or in combination with more conventional tuberculosis treatments in humans.

Prodrugs for the treatment of neglected diseases

Recently, World Health Organization (WHO) and Medicins San Frontieres (MSF) proposed a classification of diseases as global, neglected and extremely neglected. Global diseases, such as cancer, cardiovascular and mental (CNS) diseases represent the targets of the majority of the R&D efforts of pharmaceutical companies. Neglected diseases affect millions of people in the world yet existing drug therapy is limited and often inappropriate. Furthermore, extremely neglected diseases affect people living under miserable conditions who barely have access to the bare necessities for survival. Most of these diseases are excluded from the goals of the R&D programs in the pharmaceutical industry and therefore fall outside the pharmaceutical market. About 14 million people,mainly in developing countries, die each year from infectious diseases. From 1975 to 1999,1393 new drugs were approved yet only 1% were for the treatment of neglected diseases[3]. These numbers have not changed until now, so in those countries there is an urgent need for the design and synthesis of new drugs and in this area the prodrug approach is a very interesting field. It provides, among other effects, activity improvements and toxicity decreases for current and new drugs, improving market availability. It is worth noting that it is essential in drug design to save time and money, and prodrug approaches can be considered of high interest in this respect. The present review covers 20 years of research on the design of prodrugs for the treatment of neglected and extremely neglected diseases such as Chagas' disease (American trypanosomiasis), sleeping sickness (African trypanosomiasis), malaria, sickle cell disease, tuberculosis, leishmaniasis and schistosomiasis.

Different roles of the two high-oxygen-affinity terminal oxidases of Brucella suis: Cytochrome c oxidase, but not ubiquinol oxidase, is required for persistence in mice

The survival of Brucella suis mutant strains in mice demonstrated different roles of the two high-oxygen-affinity terminal oxidases. The cbb3-type cytochrome c oxidase was essential for chronic infection in oxygen-deficient organs. Lack of the cytochrome bd ubiquinol oxidase led to hypervirulence of bacteria, which could rely on nitrite accumulation inhibiting the inducible nitric oxide synthase of the host.

Differential use of the two high-oxygen-affinity terminal oxidases of Brucella suis for in vitro and intramacrophagic multiplication

Expression of the high-oxygen-affinity cytochrome cbb3 and cytochrome bd ubiquinol oxidases of Brucella suis was studied in vitro and in the intramacrophagic niche, which was previously proposed to be oxygen limited. The cytochrome cbb3 oxidase was exclusively expressed in vitro, whereas the cytochrome bd oxidase was preferentially used inside macrophages and contributed to intracellular bacterial replication.